Bioatla Inc (NASDAQ:BCAB) — Market Cap & Net Worth
Market Cap & Net Worth: Bioatla Inc (BCAB)
Bioatla Inc (NASDAQ:BCAB) has a market capitalization of $2.44 Million ($2.44 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29860 globally and #6081 in its home market, demonstrating a 13.08% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bioatla Inc's stock price $1.47 by its total outstanding shares 1659554 (1.66 Million). Also see balance sheet size of Bioatla Inc for a full breakdown of the balance sheet.
Bioatla Inc Market Cap History: 2020 to 2026
Bioatla Inc's market capitalization history from 2020 to 2026. Data shows change from $56.44 Million to $2.44 Million (-41.17% CAGR). Also see Bioatla Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Bioatla Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #872 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #2784 of 3165 |
Weight: Bioatla Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Bioatla Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bioatla Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check BCAB live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.47x
Bioatla Inc's market cap is 0.47 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $56.44 Million | $429.00K | -$35.85 Million | 131.57x | N/A |
| 2021 | $32.58 Million | $250.00K | -$95.40 Million | 130.31x | N/A |
| 2024 | $981.13K | $11.00 Million | -$69.78 Million | 0.09x | N/A |
| 2025 | $942.13K | $2.00 Million | -$59.61 Million | 0.47x | N/A |
Competitor Companies of BCAB by Market Capitalization
Companies near Bioatla Inc in the global market cap rankings as of September 18, 2026. Review BCAB intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Bioatla Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Bioatla Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Bioatla Inc's market cap moved from $56.44 Million to $ 2.44 Million, with a yearly change of -41.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.44 Million | +158.94% |
| 2025 | $942.13K | -3.97% |
| 2024 | $981.13K | -75.97% |
| 2023 | $4.08 Million | -70.18% |
| 2022 | $13.69 Million | -57.97% |
| 2021 | $32.58 Million | -42.28% |
| 2020 | $56.44 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Bioatla Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.44 Million USD |
| MoneyControl | $2.44 Million USD |
| MarketWatch | $2.44 Million USD |
| marketcap.company | $2.44 Million USD |
| Reuters | $2.44 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bioatla Inc
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); a… Read more